Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) has issued an update.
NeuroScientific Biopharmaceuticals Limited reported its Appendix 4D results for the half-year ended 31 December 2025, highlighting a 359% increase in revenue from ordinary activities to $436,301 compared with the prior corresponding period. Despite the revenue growth, the company posted a loss from ordinary activities and overall loss attributable to owners of $1,699,413, up 362% year on year, did not declare a dividend for the half-year, and reported a fall in net tangible assets per share to 1.98 cents from 3.23 cents, underscoring ongoing investment and balance sheet pressure typical of early-stage biopharmaceutical firms.
The interim financial statements for the half-year were reviewed by the company’s auditors, with the review report included in the interim financial report released to the market. The results, signed off by chairman Rob McKenzie on 25 February 2026, signal that while NeuroScientific is generating higher operating revenue, it remains loss-making and reliant on its asset base to fund continuing development, a key consideration for shareholders monitoring dilution risk and future capital needs.
The most recent analyst rating on (AU:NSB) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Neuroscientific Biopharmaceuticals Ltd. stock, see the AU:NSB Stock Forecast page.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Limited is an Australian biotechnology company focused on developing pharmaceutical treatments, operating in the biopharmaceuticals industry. It targets neurological and related conditions, with activities centered on research, development, and progression of its drug candidates through the clinical and regulatory pipeline.
Average Trading Volume: 373,543
Technical Sentiment Signal: Sell
Current Market Cap: A$36.58M
Learn more about NSB stock on TipRanks’ Stock Analysis page.